Revolution Medicines Publishes First IPO Filing

Jan. 20, 2020 6:54 PM ETRevolution Medicines, Inc. (RVMD)


  • Revolution Medicines has filed to raise $100 million in an IPO, although that is a typical placeholder figure.
  • The firm is advancing a pipeline of drug candidates target the RAS and mTOR cancer pathways.
  • RVMD has an enviable investment and collaboration relationship with pharma giant Sanofi.
  • Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »

Quick Take

Revolution Medicines (NASDAQ:RVMD) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.

The company is a clinical stage biopharma developing treatments for cancers with an emphasis on the RAS and mTOR signaling pathways.

RVMD has a significant partnership collaboration with investor Sanofi (SNY), and I await more information about management's proposed pricing and valuation expectations.

Company & Technology

Redwood City, California-based Revolution was founded to advance a pipeline of drug candidates for the treatment of a variety of cancers, including solid tumors.

Management is headed by President and CEO Mark Goldsmith, M.D., Ph.D, who has been with the firm since November 2014 and was previously President and CEO of Constellation Pharmaceuticals.

Below is a brief overview video of SHP2 inhibitor aspects:

Source: ecancer

The firm's lead candidate, RMC-4630, is currently in Phase 1/2 trials and is an SHP2 inhibitor that seeks to overcome resistance to current RTKi cancer treatment regimens.

Below is the current status of the company's drug development pipeline:

Source: S-1

Investors in the firm have invested at least $305 million and include Third Rock Ventures, The Column Group, and Sanofi Research Invest (SNY).

Market & Competition

According to a 2019 market research report by ResearchandMarkets, the global market for solid tumor cancer treatment was more than $121 billion in 2018 and is expected to reach $424 billion by 2027. This represents a forecast very strong CAGR (Compound Annual Growth Rate) of 15.0% from 2019 to 2027.

Key elements driving this expected growth are an increase in breast cancer incidence as well as lung cancer due to rising air pollution and the number of cigarette smokers worldwide. North America accounts for 33.6% of demand for solid tumor cancer treatments followed by Europe at 30.2% and the Asia Pacific region

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis. Get started with a free trial!

This article was written by

Donovan Jones profile picture
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.